HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ardisianone, a natural benzoquinone, efficiently induces apoptosis in human hormone-refractory prostate cancers through mitochondrial damage stress and survivin downregulation.

AbstractBACKGROUND:
Increasing evidence suggests that mitochondria play a central role in regulating cell apoptosis. Survivin, an inhibitor of apoptosis protein (IAP) family member, mediates resistance to cancer chemotherapy particularly in prostate cancers. Therefore, development of anticancer agents targeting mitochondria and survivin is a potential strategy.
METHOD:
Cell proliferation was examined by sulforhodamine B, CFSE staining, and clonogenic assays. Mitochondrial membrane potential (ΔΨ(m) ) and reactive oxygen species (ROS) were detected by flow cytometric analysis. Protein expression was detected by Western blot. RNA levels were examined by reverse transcription polymerase chain reaction assay. Overexpression of constitutively active Akt was also used in this study.
RESULTS:
Ardisianone, a natural benzoquinone derivative, displayed anti-proliferative and apoptotic activities against human hormone-refractory prostate cancer cells (HRPC), PC-3, and DU-145. Ardisianone dramatically induced mitochondrial damage, identified by downregulation of Bcl-2 family proteins, ROS production, and loss of ΔΨ(m) . Ardisianone also inhibited Akt and mTOR/p70S6K pathways and induced a fast downregulation of survivin, leading to activation of mitochondria-involved caspase cascades. Overexpression of constitutively active Akt partly rescued ardisianone-mediated apoptotic signaling cascades. Furthermore, a long-term treatment of ardisianone caused an increase of endoplasmic reticulum (ER) stress, upregulation of cIAP1 and cIAP2, and apoptosis-inducing factor (AIF)-mediated caspase-independent apoptosis.
CONCLUSIONS:
The data suggest that the ardisianone induces apoptosis in human prostate cancers through mitochondrial damage stress, leading to the inhibition of mTOR/p70S6K pathway, downregulation of Bcl-2 family members, degradation of survivin, and activation of caspase cascades. The data provide evidence supporting that ardisianone is a potential anticancer agent against HRPCs.
AuthorsChia-Chun Yu, Ping-Jung Wu, Jui-Ling Hsu, Yunn-Fang Ho, Lih-Ching Hsu, Yu-Jia Chang, Hsun-Shuo Chang, Ih-Sheng Chen, Jih-Hwa Guh
JournalThe Prostate (Prostate) Vol. 73 Issue 2 Pg. 133-45 (Jan 2013) ISSN: 1097-0045 [Electronic] United States
PMID22674285 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Wiley Periodicals, Inc.
Chemical References
  • BIRC5 protein, human
  • Benzoquinones
  • Inhibitor of Apoptosis Proteins
  • Reactive Oxygen Species
  • Survivin
  • ardisianone A
Topics
  • Apoptosis (drug effects, physiology)
  • Benzoquinones (pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Down-Regulation (drug effects, physiology)
  • Humans
  • Inhibitor of Apoptosis Proteins (antagonists & inhibitors, metabolism)
  • Male
  • Membrane Potential, Mitochondrial (drug effects, physiology)
  • Mitochondria (drug effects, metabolism)
  • Oxidative Stress (drug effects, physiology)
  • Prostatic Neoplasms (drug therapy, metabolism)
  • Reactive Oxygen Species (metabolism)
  • Survivin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: